Aug 11, 2014 - ing potential pharmacogenetic testing as a tool for individual- ized therapy. For example, mutations in t
Current Literature In Clinical Science
SCN1A and Febrile Seizures in Mesial Temporal Epilepsy: An Early Signal to Guide Prognosis and Treatment?
Epilepsy, Hippocampal Sclerosis and Febrile Seizures Linked by Common Genetic Variation Around SCN1A. Kasperavicˇiu¯ te D, Catarino CB, Matarin M, Leu C, Novy J, Tostevin A, Leal B, Ellen Hessel EVS, Hallmann K, Hildebrand MS, Dahl H-HM, Ryten M, Trabzuni D, Ramasamy A, Alhusaini S, Doherty CP, Dorn T, Hansen J, Kra¨mer G, Steinhoff BJ, Zumsteg D, Duncan S, Ka¨lvia¨inen RK, Eriksson KJ, Kantanen A-M, Pandolfo M, Gruber-Sedlmayr U, Schlachter K, Reinthaler EM, Stogmann E, Zimprich F, The´aˆtre E, Smith C, O’Brien TJ, Tan KM, Petrovski S, Robbiano A, Paravidino R, Zara F, Striano P, Sperling MR, Buono RJ, Hakonarson H, Chaves J, Costa PP, Silva BM, da Silva AM, de Graan PNE, Koeleman BPC, Becker A, Schoch S, von Lehe M, Reif PS, Rosenow F, Becker F, Weber Y, Lerche H, Ro¨ssler K, Buchfelder M, Hamer HM, Kobow K, Coras R, Blumcke I, Scheffer IE, Berkovic SF, Weale ME, UK Brain Expression Consortium Delanty N, Depondt C, Cavalleri GL, Kunz WS, Sisodiya SM. Brain 2013:36;3140–3150
Epilepsy comprises several syndromes, amongst the most common being mesial temporal lobe epilepsy with hippocampal sclerosis. Seizures in mesial temporal lobe epilepsy with hippocampal sclerosis are typically drug-resistant, and mesial temporal lobe epilepsy with hippocampal sclerosis is frequently associated with important co-morbidities, mandating the search for better understanding and treatment. The cause of mesial temporal lobe epilepsy with hippocampal sclerosis is unknown, but there is an association with childhood febrile seizures. Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs. We undertook a genome-wide association study in 1018 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 7552 control subjects, with validation in an independent sample set comprising 959 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 3591 control subjects. To dissect out variants related to a history of febrile seizures, we tested cases with mesial temporal lobe epilepsy with hippocampal sclerosis with (overall n = 757) and without (overall n = 803) a history of febrile seizures. Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 x 10-9, odds ratio (A) = 1.42, 95% confidence interval: 1.26–1.59]. In a cohort of 172 individuals with febrile seizures, who did not develop epilepsy during prospective follow-up to age 13 years, and 6456 controls, no association was found for rs7587026 and febrile seizures. These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.
Commentary Although uncommon, the progression of febrile seizures (FS) early in life to mesial temporal lobe epilepsy with MTS is well-described; however, underlying mechanisms and predictors are poorly understood. Proposed mechanisms include prolonged FS at an early age damaging the hippocampus, initial hippocampal injury peri- or prenatally, or a hippocampal formation genetically predisposed to MTS triggered or activated by remote FS. This latter proposed mechanism is associated with the largest number of epilepsies demonstrating a history of FS and an association with variants within the alpha Epilepsy Currents, Vol. 14, No. 4 (July/August) 2014 pp. 189–190 © American Epilepsy Society
1 subunit of voltage dependent sodium channels (SCN1A) (8). The SCN1A-related epilepsies compose a continuum of disorders with incomplete penetrance and variable expressivity. The febrile-associated epilepsies range from self-limited simple FS and generalized epilepsy with febrile seizures plus (GEFS+) to Dravet syndrome, also known as severe myoclonic epilepsy in infancy (SMEI). SCN1A phenotypes also include myoclonic-astatic epilepsy, or Doose syndrome, LennoxGastaut syndrome (LGS), infantile spasms, and vaccine-related encephalopathy and seizures (7). The overall prevalence of SCN1A-related epilepsies is not known. MTS is a relatively uncommon finding in these epilepsies (1,6). In fact, Dravet syndrome is not associated with hippocampal sclerosis (7). SCN1A-associated epilepsies can be inherited in an autosomal dominant manner, or as a de novo mutation. SCN1A is part of a cluster of sodium channel genes encoded on chromo-
189
SCN1A and Febrile Seizures in Mesial Temporal Epilepsy
some 2q24 that includes SCN2A and SCN3A (5). SCN1A encodes a voltage-gated sodium channel alpha subunit. The alpha subunit of sodium channels forms the membrane pore. Each alpha subunit protein has four domains with six transmembrane segments connected by loops. The majority of SCN1A mutations cluster in the C-terminus and the pore loops in the first three domains of the protein (5,10). The pathophysiology of SCN1A mutations is a decrease in the activity of GABAergic inhibitory neurons. For example, most of the mutations that cause Dravet syndrome (SMEI) result in loss of function, whereas mutations that cause GEFS+ are missense, likely altering channel activity (3). However, about 5% of individuals with mutation-positive SMEI have a familial missense SCN1A mutation associated with a milder phenotype (i.e., GEFS+) in other family members (5). The study by Kasperaviciute et al., is a multicenter, multinational genetic association study involving a large cohort of subjects with MTS with and without a history of FS. The aim of this study was to identify an association, if not a mechanism, of the most common focal-onset epilepsy when associated with early FS. A detailed meta-analysis demonstrated a target at the sodium channel gene cluster on chromosome 2q24.3 (rs7587026, within an intron of the SCN1A gene). Those subjects with early FS followed to nearly age 15 without developing hippocampal sclerosis HS did not possess the mutation. Although this study does not explain whether FS cause MTS, or whether pre-existing hippocampal abnormalities predispose to FS (2), it suggests that patients with MTS, with or without a history of FS possess different underlying pathogenetic mechanisms. The study controls for the specificity of the association for MTS + FS rather than FS alone, since developing epilepsy following a history of FS is most often apparent by age 15 (4). No association of the rs7587026 with FS where patients did not develop epilepsy was found in comparison with controls from the same cohort. The authors reported observing a signal in MTS + FS not due to a history of FS alone. In addition, a dissociation was demonstrated where no significant relationship was detected in a group of patients with other partial epilepsies and a history of FS. The authors reported that their genetic association strategy did not differentiate between cell types (interneurons as proposed in Dravet syndrome vs principal neurons). Additionally, the authors did not address possible mechanisms underlying the specificity of hippocampal pathophysiology, or insight as to the critical age range of onset. Translational implications of this study include developing potential pharmacogenetic testing as a tool for individualized therapy. For example, mutations in the alpha-unit of the SCN1A gene have been associated with decreased efficacy of sodium channel blocking anti-epileptic medications. A single nucleotide polymorphism in SCN1A is associated with carbamazepine-resistant epilepsy. As a result, such individu-
190
als require higher maintenance dose of carbamazepine (9). Of note, children with SCN1A-related epilepsy may be at high risk of sudden unexpected death in epilepsy (SUDEP). SCN1A has been closely connected with a number of other voltage-gated sodium channel genes (i.e., SCN1B, SCN2A, SCN3A). These genes may contribute both pathophysiologically and phenotypically to a number of the genetic epilepsies. Moreover, phenotypic expression of these other genes can overlap with those of SCN1A. This information suggests a heterogeneous group of genetic epilepsies. Nevertheless, this important well-organized multinational study contributes a better understanding of SCN1A-related mesial temporal lobe epilepsy with hippocampal sclerosis. Moreover, it provides a systematic approach that could inevitably lead to both prognosis and potential therapies in a subgroup of children with MTLE and a history of FS. by Marvin A Rossi, MD, PhD References 1. Abou-Khalil B, Ge Q, Desai R, Ryther R, Bazyk A, Bailey R, Haines JL, Sutcliffe JS, George AL Jr. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology 2001;57:2265– 2272.2. 2. Cendes F. Febrile seizures and mesial temporal sclerosis. Curr Opin Neurol 2004;17:161–164. 3. Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 2010;51:1650–1658. 4. Neligan A, Bell GS, Giavasi C, Johnson AL, Goodridge DM, Shorvon SD, et al. Long-term risk of developing epilepsy after febrile seizures: a prospective cohort study. Neurology 2012;78:1166–1170. 5. Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. Hum Mutat 2005;25:535–542. 6. Mantegazza M, Gambardella A, Rusconi R, Schiavon E, Annesi F, Cassulini RR, Labate A, Carrideo S, Chifari R, Canevini MP, Canger R, Franceschetti S, Annesi G, Wanke E, Quattrone A. Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc Natl Acad Sci U S A 2005;102:18177–18182. 7. Miller IO, Sotero de Menezes MA. SCN1A-related seizure disorders. GeneReviews. 2011. http://www.ncbi.nlm.nih.gov. Accessed on March 25, 2014. 8. Oliva M, Berkovic SF, Petrou S. Sodium channels and the neurobiology of epilepsy. Epilepsia 2012;53:1849–1859. 9. Sterjev Z, Kiteva G, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska TJ, Nestorovska KA, Matevska N,Trajkovik-Jolevska S, Dimovski AJ, Suturkova, Lj. Influence of the SCN1A IVS5N +5 G>A polymorphism on therapy. BJMG 2012;15:19-24. 10. Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 2011;76:594–600.
American Epilepsy Society Epilepsy Currents Journal Disclosure of Potential Conflicts of Interest Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts. 1.
Identifying information. Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.
2.
The work under consideration for publication. This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.
3.
Relevant financial activities outside the submitted work. This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.
4.
Other relationships Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
American Epilepsy Society Epilepsy Currents Journal Disclosure of Potential Conflicts of Interest Section #1 Identifying Information 1.
Today’s Date: 5/14/2014
2.
First Name Marvin
3.
Are you the Main Assigned Author?
Last Name Rossi Degree MD, PhD Yes
No
If no, enter your name as co-author: 4.
Manuscript/Article Title: ISCN1A and Febrile Seizures in Mesial Temporal Epilepsy: An Early Signal to Guide Prognosis and Treatment?
5. Journal Issue you are submitting for: 14.4 Section #2 The Work Under Consideration for Publication Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table. Type
1.
Grant
2.
Consulting fee or honorarium
3.
Support for travel to meetings for the study or other purposes
4.
Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like
5.
Payment for writing or reviewing the manuscript
6.
Provision of writing assistance, medicines, equipment, or administrative support.
7.
Other
No
Money Paid to You
Money to Your Institution*
Name of Entity
Comments**
* This means money that your institution received for your efforts on this study. ** Use this section to provide any needed explanation.
Page 2
8/11/2014
Section #3 Relevant financial activities outside the submitted work. Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission. Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table. Type of relationship (in alphabetical order)
1.
Board membership
2.
Consultancy
3.
Employment
4.
Expert testimony
5.
Grants/grants pending
6.
Payment for lectures including service on speakers bureaus
7.
Payment for manuscript preparation.
8.
Patents (planned, pending or issued)
9.
Royalties
No
Money Paid to You
Money to Your Institution*
Name of Entity
Comments**
10. Payment for development of educational presentations 11. Stock/stock options 12. Travel/accommodations/meeti ng expenses unrelated to activities listed.** 13. Other (err on the side of full disclosure) * This means money that your institution received for your efforts. ** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.
Section #4 Other relationships Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? No other relationships/conditions/circumstances that present a potential conflict of interest. Yes, the following relationships/conditions/circumstances are present:
Thank you for your assistance. Epilepsy Currents Editorial Board
Page 3
8/11/2014
